Qbic I

Qbic I, established in 2013, is an early-stage venture capital fund based in Ghent, Belgium. It focuses on investing in software, deep tech, biotech, and medtech sectors. The fund, managed by Qbic Venture Partners, supports spin-off companies from Ghent, Brussels, and Antwerp university associations, as well as VITO. It has over €30 million under management and is backed by both public and private investors. Qbic I's investment approach involves early, in-depth analysis and subsequent hands-on involvement in portfolio companies.

Sofie Baeten

CEO

Vincent Lenders

Investment Analyst

Steven Leuridan

Partner

Cedric Van Nevel

Investment Manager

Tom Smets

Investment Analyst

Past deals in Belgium

Confo Therapeutics

Series B in 2024
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

EyeD Pharma

Venture Round in 2021
EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

Accelleran

Series B in 2021
Accelleran, founded in 2013 and based in Antwerp, Belgium, specializes in delivering Open RAN-aligned Private 5G networks tailored for enterprises of all sizes. The company's solutions facilitate the deployment of multi-vendor, disaggregated Private 5G networks, comparable in ease to WiFi installations. By utilizing cloud-native techniques, Accelleran's offerings provide flexibility, innovation, and scalability while ensuring hardware independence. This approach enables businesses to achieve network virtualization, enhancing their ability to serve private, public, and neutral host networks. Accelleran aims to enhance user experiences through intelligent automation and real-time network control, positioning itself as a viable alternative to traditional mobile telecom systems.

QustomDot

Seed Round in 2020
QustomDot is a company based in Ghent, Belgium, specializing in the development and manufacturing of on-chip grade and cadmium-free quantum dots. These tiny semiconductor nanoparticles are designed to transform ultraviolet or blue light into pure colors, enhancing the image quality of various display technologies. QustomDot's products are applicable in LED/LCD televisions, smartphones, smartwatches, virtual and augmented reality goggles, and LED lighting solutions. The company not only produces quantum dots but also assists customers in integrating these advanced materials into their products, helping to improve color gamut and energy efficiency. Founded in 2020, QustomDot is focused on innovation in the field of advanced materials.

MRM Health NV

Series A in 2020
MRM Health NV is a biopharmaceutical company based in Ghent, Belgium, that specializes in developing microbiome-based therapeutics for metabolic diseases. Founded in early 2020 as a subsidiary of MRM Technologies, the company collaborates with the Flemish Institute of Biotechnology (VIB) to translate scientific research into practical applications. MRM Health is focused on innovative drug development, particularly its lead candidate MH002, aimed at treating Inflammatory Bowel Disease (IBD), which encompasses conditions such as Ulcerative Colitis and Crohn's disease. Through its research and development efforts, MRM Health seeks to advance therapeutic options based on the human microbiome.

Calltic

Series A in 2020
Calltic, founded in 2017 and located in Gent, Belgium, specializes in fraud detection services for the telecommunications industry. The company offers an innovative approach to combating telecom fraud, focusing on the rapid and accurate detection of SIM boxes through advanced pattern recognition methods. By utilizing a single tool, Calltic effectively identifies both on-net and off-net fraud, enabling its clients to significantly reduce the financial losses associated with fraudulent activities. This comprehensive solution aims to outperform traditional call detail record profiling techniques, providing a more efficient way for telecom operators to protect their revenues.

Biotalys

Series C in 2019
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.

Unifly

Series B in 2019
Unifly is a developer of unmanned traffic management software focused on the secure integration of drones into global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers who recognized the need for effective management of the increasing number of drones. Unifly's award-winning platform connects authorities and drone operators, allowing for real-time monitoring and management of drone traffic, while providing pilots with essential information regarding the legal status of their flights. The platform is already utilized by national authorities in Germany, Denmark, Austria, and Belgium, and Unifly is also active in the United States and several projects worldwide, including Africa and Asia. By fostering collaboration with various stakeholders, Unifly aims to enhance airspace safety and facilitate the seamless integration of drones into everyday life, addressing critical concerns regarding safety and oversight in both recreational and commercial drone activities.

EyeD Pharma

Funding Round in 2019
EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

Laminaria

Venture Round in 2017
Laminaria, founded in 2011 and based in Ostend, Belgium, specializes in manufacturing wave energy converter equipment. The company is at the forefront of developing technology designed to harness renewable wave energy, using a system that converts tilting and translating motions into power through mooring ropes connected to generators. Laminaria leads the LAMWEC project, a consortium of ocean energy experts that includes organizations such as EMEC, Innosea, Ghent University, and TTI Testing. Through its innovative technology, Laminaria aims to significantly impact the renewable energy landscape by advancing the effectiveness and efficiency of wave energy conversion.

Smartnodes

Seed Round in 2016
SmartNodes S.A., founded in 2014 and based in Liege, Belgium, specializes in innovative lighting systems and solutions aimed at enhancing urban environments. The company's flagship product, the smart lighting system (SLS-G3), integrates various components including node units and power units, alongside systems for smart lighting control and noise monitoring. SmartNodes focuses on providing energy-efficient solutions that lower power consumption while ensuring safety and visual comfort for users. By adjusting light levels based on the presence of pedestrians and vehicles, the company effectively reduces light pollution and the ecological footprint of public lighting systems. Its offerings cater to both public authorities and the private sector, aiming to transform urban lighting through advanced technology and sustainability. As of July 2019, SmartNodes operates as a subsidiary of Lacroix SA.

Unifly

Seed Round in 2015
Unifly is a developer of unmanned traffic management software focused on the secure integration of drones into global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers who recognized the need for effective management of the increasing number of drones. Unifly's award-winning platform connects authorities and drone operators, allowing for real-time monitoring and management of drone traffic, while providing pilots with essential information regarding the legal status of their flights. The platform is already utilized by national authorities in Germany, Denmark, Austria, and Belgium, and Unifly is also active in the United States and several projects worldwide, including Africa and Asia. By fostering collaboration with various stakeholders, Unifly aims to enhance airspace safety and facilitate the seamless integration of drones into everyday life, addressing critical concerns regarding safety and oversight in both recreational and commercial drone activities.

Confo Therapeutics

Venture Round in 2015
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Track4c

Venture Round in 2014
Track4C, founded in 2012, specializes in providing end-to-end container and cargo tracking services aimed at enhancing supply chain transparency. The company delivers affordable and effective solutions by offering both hardware and software tools necessary for tracking containers or fleets. Utilizing GSM technology, Track4C enables clients to access real-time information through a web-based dashboard, facilitating seamless integration with existing ICT systems. This approach significantly reduces administrative burdens and operational costs for businesses. The company benefits from support by various business incubators and has received substantial funding from prominent venture capital firms in Belgium. Its management team possesses extensive experience in telecommunications and other diverse fields, positioning Track4C as a key player in the logistics and supply chain sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.